[go: up one dir, main page]

WO2018099680A1 - Sels de citrate d'un inhibiteur de janus kinase (jak) - Google Patents

Sels de citrate d'un inhibiteur de janus kinase (jak) Download PDF

Info

Publication number
WO2018099680A1
WO2018099680A1 PCT/EP2017/078044 EP2017078044W WO2018099680A1 WO 2018099680 A1 WO2018099680 A1 WO 2018099680A1 EP 2017078044 W EP2017078044 W EP 2017078044W WO 2018099680 A1 WO2018099680 A1 WO 2018099680A1
Authority
WO
WIPO (PCT)
Prior art keywords
baricitinib
dicitrate
monocitrate
range
amorphous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2017/078044
Other languages
English (en)
Inventor
Verena Adamer
Erwin Paul Schreiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of WO2018099680A1 publication Critical patent/WO2018099680A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Definitions

  • the present invention relates to citrate salts of baricitinib, in particular to baricitinib mono- and dicitrate, as well as to crystalline and amorphous forms thereof, and to methods for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising one or more citrate salts of baricitinib, and to the use of said pharmaceutical composition as a medicament, in particular for the treatment of rheumatoid arthritis.
  • Baricitinib a Janus Kinase (JAK) inhibitor
  • JNK Janus Kinase
  • baricitinib is currently in pre -registration for the treatment of rheumatoid arthritis.
  • Chemically designated as ⁇ l-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l-yl]azetidin-3-yl ⁇ acetonitrile, baricitinib may be represented by the chemical structure as depicted in Formula I:
  • WO 2009/114512 Al discloses processes for the preparation of baricitinib free base, which is obtained as an off-white solid in unknown form in Examples 70 and 78.
  • Example 71 of the same application provides a process for the preparation of baricitinib phosphate, which is obtained as a white crystalline solid having a melting point of 187 °C.
  • a process for the preparation of baricitinib trifluoroacetate is given in Example 1 of WO 2009/114512 Al which is obtained in unknown state.
  • CN 105601635 discloses crystalline Form A, Form H and Form I of baricitinib phosphate and methods for their preparation.
  • Example 71 of WO 2009/114512 resulted in a crystalline form of baricitinib phosphate, which is denominated "Form X" in CN105601635, a PXRD of said "Form X" being displayed in Figure 16 of CN105601635.
  • CN105566332 two crystalline forms of baricitinib trifluoroacetate designated Form A and Form B as well as methods for their preparation are disclosed.
  • Example 1 of WO 2009/114512 Al leads to a "semi-crystal" of baricitinib trifluoroacetate, a PXRD of said "semi-crystal” being displayed in Figure 15 of CN CN105566332.
  • solubility, dissolution rate and gastrointestinal permeability are fundamental parameters that control rate and extent of drug absorption and its bioavailability.
  • the water solubility of a drug is a crucial property that plays an important role in the absorption of the drug after oral administration. It also governs the possibility of preparing liquid formulations intended for oral or parenteral administration of a drug.
  • salt formation is a well-known means of enhancing the aqueous solubility of an acidic or basic drug substance, the actual increase in aqueous solubility varies depending on counter-ions. Hence, the identification of a particularly highly soluble salt is not predictable and therefore remains an empirical exercise.
  • the present invention provides citrate salts of baricitinib, showing superior aqueous solubilities and dissolution profiles compared to known baricitinib free base, baricitinib phosphate and baricitinib trifluoro acetate.
  • the invention refers to baricitinib mono- and dicitrate as well as to crystalline and amorphous forms thereof.
  • the invention relates to a crystalline form of baricitinib monocitrate characterized by having a powder X-ray diffractogram comprising reflections at 2-theta angles of (4.6 ⁇ 0.2)°, (14.7 ⁇ 0.2)° and (18.2 ⁇ 0.2)°, when measured at RT with Cu-Kalphal,2 radiation having a wavelength of 0.15419 nm.
  • the invention refers to a crystalline form of baricitinib dicitrate characterized by having a powder X-ray diffractogram comprising reflections at 2-theta angles of (5.1 ⁇ 0.2)°, (14.5 ⁇ 0.2)°, (16.5 ⁇ 0.2)°, (23.1 ⁇ 0.2)° and (24.2 ⁇ 0.2)°, when measured at RT with Cu- Kalphal,2 radiation having a wavelength of 0.15419 nm.
  • the invention further relates to processes for the preparation of the baricitinib citrate salts either in their crystalline or amorphous form.
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising an effective and/or predetermined amount of one or more baricitinib citrate salts in crystalline and/or amorphous form and one or more pharmaceutically acceptable excipient(s) and to the use of said pharmaceutical composition as a medicament, in particular for the treatment of rheumatoid arthritis.
  • baricitinib refers to the compound with the chemical name ⁇ l-(Ethylsulfonyl)-3-[4- (7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]azetidin-3-yl ⁇ acetonitrile, which is represented by the chemical structure as depicted in Formula I of the present invention.
  • baricitinib used in isolation indicates the free base form.
  • baricitinib citrate refers to the compound with the chemical name ⁇ 1- (Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]azetidin-3- yl ⁇ acetonitrile citrate, which is represented by the chemical structure as depicted in Formula (II) of the present invention, wherein n is in the range of from 0.3 to 2.5, preferably from 0.4 to 2.1.
  • baricitinib monocitrate refers to the compound with the chemical name Il(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]azetidin-3- yl ⁇ acetonitrile monocitrate, which is represented by the chemical structure as depicted in Formula (II) of the present invention, wherein n is in the range of from 0.7 to 1.3, preferably from 0.8 to 1.2, more preferably from 0.9 to 1.1, and most preferably n is 1.0.
  • n may be selected from the group consisting of 0.7, 0.8, 0.9, 1.0, 1.1, 1.2 and 1.3.
  • baricitinib dicitrate refers to the compound with the chemical name (1 - (Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]azetidin-3- yl ⁇ acetonitrile dicitrate, which is represented by the chemical structure as depicted in Formula (II) of the present invention, wherein n is in the range of from 1.7 to 2.3, preferably from 1.8 to 2.2, more preferably from 1.9 to 2.1, and most preferably n is 2.0.
  • n may be selected from the group consisting of 1.7, 1.8, 1.9, 2.0, 2.1, 2.2 and 2.3.
  • room temperature refers to a temperature in the range of from 20
  • the term "measured at a temperature in the range of from 20 to 30 °C" refers to a measurement under standard conditions.
  • standard conditions mean a temperature in the range of from 20 to 30 °C, i.e. at room temperature, such as 22 °C.
  • standard conditions can additionally mean a measurement under 35-65% relative humidity, such as 50% relative humidity.
  • reflection with regards to powder X-ray diffraction as used herein, means peaks in an X-ray diffractogram, which are caused at certain diffraction angles (Bragg angles) by constructive interference from X-rays scattered by parallel planes of atoms in solid material, which are distributed in an ordered and repetitive pattern in a long-range positional order.
  • a solid material is classified as crystalline material, whereas amorphous material is defined as solid material, which lacks long-range order and only displays short-range order, thus resulting in broad scattering.
  • long-range order e.g.
  • the term "essentially the same" with reference to PXRD means that variabilities in peak positions and relative intensities of the peaks are to be taken into account.
  • a typical precision of the 2-Theta values is in the range of ⁇ 0.2° 2-Theta, preferably in the range of ⁇ 0.1° 2-Theta.
  • a diffraction peak that usually appears at 4.6° 2-Theta for example can appear between 4.4° and 4.8° 2-Theta, preferably between 4.5° and 4.7° 2-Theta on most X-ray diffractometers under standard conditions.
  • relative peak intensities will show inter-apparatus variability as well as variability due to degree of crystallinity, preferred orientation, sample preparation and other factors known to those skilled in the art and should be taken as qualitative measure only.
  • the term "substantially pure" with reference to a particular polymorphic form means that the polymorphic form includes less than 10%, preferably less than 5%, more preferably less than 3%, most preferably less than 1% by weight of any other physical forms of the compound.
  • the presence of more than one polymorph in a sample may be determined by techniques such as x-ray powder diffraction (XRPD) or solid state nuclear magnetic resonance spectroscopy. For example, the presence of extra peaks in the comparison of an experimentally measured XRPD pattern with a simulated XRPD pattern may indicate more than one polymorph in the sample.
  • XRPD x-ray powder diffraction
  • solid state nuclear magnetic resonance spectroscopy for example, the presence of extra peaks in the comparison of an experimentally measured XRPD pattern with a simulated XRPD pattern may indicate more than one polymorph in the sample.
  • the simulated XRPD may be calculated from single crystal x-ray data, see Smith, D.K., "A FORTRAN Program for Calculating X-Ray Powder Diffraction Patterns," Lawrence Radiation Laboratory, Livermore, California, UCRL-7196 (April 1963) or TOP AS program (Total Pattern Analysis Solution, available through Brucker AXS Inc.).
  • solid form refers to any crystalline and amorphous phase of a substance.
  • a "predetermined amount” as used herein with regard to baricitinib citrate of the present invention refers to the initial amount of baricitinib citrate used for the preparation of a pharmaceutical composition.
  • effective amount as used herein with regard to baricitinib citrate of the present invention encompasses an amount of baricitinib citrate, which causes the desired therapeutic and/or prophylactic effect.
  • amorphous refers to a solid form of a molecule, atom, and/or ions that is not crystalline.
  • Baricitinib citrate may be referred to herein as being characterized by graphical data "as shown in" a Figure.
  • Such data can include, for example, powder X-ray difractograms (XRPD), differential scanning calorimetry (DSC) thermograms and thermogravimetric analysis (TGA) .
  • XRPD powder X-ray difractograms
  • DSC differential scanning calorimetry
  • TGA thermogravimetric analysis
  • the person skilled in the art understands that factors such as variations in instrument type, response and variations in sample directionality, sample concentration and sample purity may lead to small variations for such data when presented in graphical form, for example variations relating to the exact peak positions and intensities.
  • a comparison of the graphical data in the Figures herein with the graphical data generated for an unknown solid form and the confirmation that two sets of graphical data relate to the same crystal form is well within the knowledge of a person skilled in the art.
  • mother liquor refers to the solution remaining after crystallization of a solid.
  • Figure 1 illustrates a representative PXRD of the crystalline form of baricitinib monocitrate of the present invention.
  • the x-axis shows the scattering angle in °2-theta
  • the y-axis shows the intensity of the scattered X-ray beam in counts of detected photons.
  • Figure 2 illustrates a representative PXRD of the amorphous form of baricitinib monocitrate of the present invention.
  • the x-axis shows the scattering angle in °2-theta
  • the y-axis shows the intensity of the scattered X-ray beam in counts of detected photons.
  • Figure 3 illustrates a representative PXRD of the crystalline form of baricitinib dicitrate of the present invention.
  • the x-axis shows the scattering angle in °2-theta
  • the y-axis shows the intensity of the scattered X-ray beam in counts of detected photons.
  • Figure 4 illustrates a representative PXRD of the amorphous form of baricitinib dicitrate of the present invention.
  • the x-axis shows the scattering angle in °2-theta
  • the y-axis shows the intensity of the scattered X-ray beam in counts of detected photons.
  • the present invention provides citrate salts of baricitinib.
  • the citrate salts of baricitinib of the present invention show superior aqueous solubilities and/or dissolution profiles compared to known baricitinib free base, baricitinib phosphate and baricitinib trifluoroacetate.
  • High solubility is the key factor for timely and complete in-vivo dissolution of the active pharmaceutical ingredient contained in an oral solid dosage form, e.g., an immediate-release tablet or a hard gelatin capsule.
  • aqueous solubility of a drug substance is the most crucial factor in designing liquid drug products because the drug substance is applied in solution. Due to their extraordinary high aqueous solubilities the baricitinib citrate salts of the present invention are very well suited for the preparation of aqueous solutions intended for parenteral or oral administration.
  • the invention relates to baricitinib citrate.
  • the invention relates to baricitinib monocitrate, characterized by the chemical structure according to Formula (II), wherein n is in the range of from 0.7 to 1.3, preferably from 0.8 to 1.2, more preferably from 0.9 to 1.1, and most preferably n is 1.0.
  • n is selected from the group consisting of 0.7, 0.8, 0.9, 1.0, 1.1, 1.2 and 1.3.
  • the invention relates to baricitinib monocitrate as defined above in amorphous or crystalline form.
  • the crystalline and amorphous forms of baricitinib monocitrate of the present invention may be characterized by PXRD.
  • they may be characterized by any one of the following embodiments or by combining two or more of the following embodiments.
  • the present invention relates to a crystalline form of baricitinib monocitrate characterized by having a PXRD comprising reflections at 2-Theta angles of:
  • baricitinib monocitrate when measured at RT with Cu-Kalphal,2 radiation having a wavelength of 0.15419 nm.
  • said crystalline form of baricitinib monocitrate is substantially pure.
  • the present invention relates to a crystalline form of baricitinib monocitrate characterized by having a PXRD essentially the same as shown in Figure 1 of the present invention, when measured at RT with Cu-Kalphal,2 radiation having a wavelength of 0.15419 nm.
  • Another embodiment of the present invention concerns an amorphous form of baricitinib monocitrate, characterized by having a PXRD comprising no reflection in the range of from 2 to 40° 2-Theta, when measured at RT with Cu-Kalphal,2 radiation having a wavelength of 0.15419 nm.
  • the invention relates to an amorphous form of baricitinib monocitrate characterized by having a PXRD essentially the same as displayed in Figure 2 of the present invention, when measured at room temperature with CuKalphal,2 radiation having a wavelength of 0.15419 nm.
  • the invention relates to baricitinib dicitrate, characterized by the chemical structure according to Formula (II), wherein n is in the range of from 1.7 to 2.3, preferably from 1.8 to 2.2, more preferably from 1.9 to 2.1, and most preferably n is 2.0. In one embodiment n is selected from the group consisting of 1.7, 1.8, 1.9, 2.0, 2.1, 2.2 and 2.3.
  • the invention relates to baricitinib dicitrate as defined above in amorphous or crystalline form.
  • the crystalline and amorphous forms of baricitinib dicitrate of the present invention may be characterized by PXRD. In particular, they may be characterized by any one of the following embodiments or by combining two or more of the following embodiments.
  • the present invention relates to a crystalline form of baricitinb dicitrate characterized by having a PXRD comprising reflections at 2-Theta angles of:
  • the present invention relates to a crystalline form of baricitinib dicitrate characterized by having a PXRD essentially the same as shown in Figure 3 of the present invention, when measured at RT with Cu-Kalphal,2 radiation having a wavelength of 0.15419 nm.
  • Another embodiment of the present invention concerns an amorphous form of baricitinib dicitrate, characterized by having a PXRD comprising no reflection in the range of from 2 to 40° 2-Theta, when measured at RT with CuKalphal ,2 radiation having a wavelength of 0.15419 nm.
  • the invention relates to an amorphous form of baricitinib dicitrate characterized by having a PXRD essentially the same as displayed in Figure 4 of the present invention, when measured at room temperature with CuKalphal, 2 radiation having a wavelength of 0.15419 nm.
  • the citrate salts of baricitinib of the present invention show improved aqueous solubilities and dissolution rates compared to baricitinib free base, baricitinib phosphate and baricitinib trifluoroacetate.
  • Comparative Example 1 of the present invention for example provides solubility data of the aforementioned salts in 0.1 N aqueous hydrochloric acid, a medium simulating the pH environment of the stomach.
  • the citrate salts of baricitinib of the present invention show a solubility, which is more than 2-fold higher than the solubility of baricitinib free base.
  • the invention relates to a process for the preparation of crystalline baricitinib monocitrate as defined above comprising the steps of:
  • step (iv) optionally separating at least a part of the crystals obtained in step (iii) from their mother liquor;
  • step (v) optionally, drying the crystals obtained in step (iii) or (iv);
  • Amorphous baricitinib monocitrate which is applied as starting material in step (i) of the above described process may be prepared by the lyophilization process described hereinafter for the preparation of amorphous baricitinib monocitrate.
  • Baricitinib free base which is used as starting material in step (ii) of the above described process may be prepared according to the procedures disclosed in Example 70 and 78 of WO 2009/114512 Al respectively. Citric acid is commercially available.
  • the one or more aprotic solvent(s) may be selected from the group consisting of nitriles, esters, ketones and hydrocarbons.
  • aprotic solvents which may be used are for example but not limited to acetonitrile, methyl acetate, ethyl acetate, methyl ethyl ketone, cyclohexanone and cyclohexane, whereat acetonitrile is most preferred.
  • the final baricitinib citrate concentration of the mixture obtained in step (i) or (ii) is preferably in the range of from 50 to 500 g/L, more preferably from 100 to 300 g/L such as 100 to 200 g/L.
  • step (i) or (ii) is slurried in step (iii), wherein slurrying in the context of the present invention relates to any motion of the mixture comprising baricitinib monocitrate, which is caused by stirring, shaking and/or ultrasonic irradiation.
  • Slurrying is performed until at least a part, preferably all of the baricitinib monocitrate has transformed to the crystalline form of the present invention.
  • the completeness of the transformation can be monitored by taking samples and investigating the samples by PXRD.
  • slurrying is performed for a period in the range of from about 6 to 48 hours, preferably from about 12 to 36 hours.
  • the obtained baricitinib monocitrate crystals or at least a part thereof may optionally be separated from their mother liquor by any conventional method such as filtration or centrifugation, most preferably by filtration.
  • the isolated crystals may be washed with a solvent, preferably with one or more aprotic solvent(s).
  • the baricitinib monocitrate crystals may optionally be dried at a temperature of about 80 °C or less, preferably of about 60 °C or less, more preferably of about 40 °C or less and most preferably the crystals are dried at RT.
  • Drying may be performed for a period in the range of from about 1 to 72 hours, preferably from about 2 to 48 hours, more preferably from about 4 to 24 hours and most preferably from about 6 to 18 hours. Drying may be performed at ambient pressure and/or under vacuum preferably at about 100 mbar or less, more preferably at about 50 mbar or less and most preferably at about 30 mbar or less, for example at about 20 mbar or less.
  • the invention relates to a process for the preparation of amorphous baricitinib monocitrate as defined above comprising:
  • step (ii) lyophilizing the solution provided in step (i);
  • the one or more water miscible organic solvent(s) may be selected from the group consisting of ethanol, acetonitrile and 1,4-dioxane.
  • Non-limiting examples and conditions of the lyophilization process are disclosed in Example 2 of the present invention.
  • the invention relates to a process for the preparation of crystalline baricitinib dicitrate as defined above comprising the steps of:
  • step (ii) slurrying the mixture obtained in step (i);
  • step (iii) optionally separating at least a part of the crystals obtained in step (ii) from their mother liquor;
  • step (iv) optionally, drying the crystals obtained in step (ii) or (iii);
  • Amorphous baricitinib dicitrate which is applied as starting material in step (i) of the above described process may be prepared either by the lyophilization process described hereinafter for the preparation of amorphous baricitinib dicitrate or by reacting one mol equivalent of baricitinib free base with 2.0 to 6.0 mol equivalent, preferably 3.0 to 5.0 mol equivalent citric acid in the presence of one or more aprotic solvent(s), followed by evaporation of the solvent.
  • Baricitinib free base which is used as starting material in step (i) of the above described process may be prepared according to the procedures disclosed in Example 70 and 78 of WO 2009/114512 Al respectively. Citric acid is commercially available.
  • the one or more aprotic solvent(s) may be selected from the group consisting of nitriles, esters, ketones and hydrocarbons.
  • aprotic solvents which may be used are for example but not limited to acetonitrile, methyl acetate, ethyl acetate, methyl ethyl ketone, cyclohexanone and cyclohexane, whereat acetonitrile is most preferred.
  • the final baricitinib citrate concentration of the mixture obtained in step (i) or (ii) is preferably in the range of from 100 to 700 g/L, more preferably of from 100 to 500g/L such as 100 to 350 g/L.
  • step (i) The mixture obtained in step (i) is slurried in step (ii), wherein slurrying in the context of the present invention relates to any motion of the mixture comprising baricitinib dicitrate, which is caused by stirring, shaking and/or ultrasonic irradiation. Slurrying is performed until at least a part, preferably all of the baricitinib dicitrate has transformed to the crystalline form of the present invention. The completeness of the transformation can be monitored by taking samples and investigating the samples by PXRD. Usually, slurrying is performed for a period in the range of from about 6 to 48 hours, preferably from about 12 to 36 hours.
  • the obtained baricitinib dicitrate crystals or at least a part thereof may optionally be separated from their mother liquor by any conventional method such as filtration or centrifugation, most preferably by filtration.
  • the isolated crystals may be washed with a solvent, preferably with one or more aprotic solvent(s).
  • the baricitinib dicitrate crystals may optionally be dried at a temperature of about 80 °C or less, preferably of about 60 °C or less, more preferably of about 40 °C or less and most preferably the crystals are dried at RT. Drying may be performed for a period in the range of from about 1 to 72 hours, preferably from about 2 to 48 hours, more preferably from about 4 to 24 hours and most preferably from about 6 to 18 hours. Drying may be performed at ambient pressure and/or under vacuum preferably at about 100 mbar or less, more preferably at about 50 mbar or less and most preferably at about 30 mbar or less, for example at about 20 mbar or less.
  • the invention relates to a process for the preparation of amorphous baricitinib dicitrate as defined above comprising:
  • step (ii) lyophilizing the solution provided in step (i);
  • the one or more water miscible organic solvent(s) may be selected from the group consisting of ethanol, acetonitrile and 1,4-dioxane.
  • Non-limiting examples and conditions of the lyophilization process are disclosed in Example 4 of the present invention.
  • the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising baricitinib citrate as defined above and one or more pharmaceutically acceptable excipient(s).
  • the pharmaceutical composition can be a pharmaceutical dosage form, such as an oral pharmaceutical dosage form, preferably a tablet.
  • the invention also relates to a pharmaceutical composition, in particular a pharmaceutical dosage form such as a capsule or a tablet, comprising
  • w-% ages are based upon the total weight of the composition.
  • the pharmaceutical composition comprises baricitinib, such as a baricitinib citrate of the present invention, preferably in an amount of from 0.5 to 25 w-%, preferably between 1 and 20 w-%), more preferably between 2 and 10 w-%, based on the total weight of the composition.
  • baricitinib such as a baricitinib citrate of the present invention
  • the pharmaceutical composition further comprises at least one excipient.
  • excipients include, but are not limited to, fillers, lubricants, disintegrants, surfactants, glidants, anti- sticking agents and mixtures thereof.
  • fillers are used to top up the volume for an appropriate oral deliverable dose, when low concentrations of the active pharmaceutical ingredients (about 25 w-% or lower) are present.
  • fillers can enhance the powder flow, facilitating for example, a uniform filling of capsules.
  • examples of fillers are calcium phosphate, calcium carbonate, magnesium carbonate, dextrose, saccharose and lactose, to name but a few.
  • Preferred amounts of fillers are 10 to 95 w-%, preferably of 20 to 95 w-%, more preferably 40 to 95 w-%), in particular 60 to 90 w-%, based on the total weight of the composition.
  • the pharmaceutical composition of the present invention may further comprise one or more disintegrants.
  • disintegrants are compounds which can promote the break up of a solid composition into smaller pieces upon contact with water.
  • examples of disintegrants are sodium carboxymethyl starch, cross-linked polyvinylpyrrolidone (crospovidone) and sodium carboxymethyl glycolate, to name but a few.
  • Disintegrants may be used in an amount of 1 to 20 w-%), preferably of 1 to 10 w-%, based on the total weight of the composition.
  • the pharmaceutical composition of the present invention may further comprise a surfactant, for example sodium lauryl sulfate, such as in an amount of 0.1 to 1.5 w-%, based on the total weight of the composition.
  • a surfactant for example sodium lauryl sulfate, such as in an amount of 0.1 to 1.5 w-%, based on the total weight of the composition.
  • the pharmaceutical composition may comprise one or more additional excipients as for example: a lubricant and/or a glidant.
  • Lubricants can reduce friction during processing steps. Examples of a lubricant are stearate, talcum powder or a fatty acid. Lubricant may be present in an amount of from 0.1 to 4 w-%, such as from 1.0 to 2.5 w-%of the total weight of the composition.
  • glidant is colloidal silicone dioxide, which may be present in an amount of from 0.1 to 3 w-% of the total weight of the composition.
  • the process for producing the pharmaceutical composition of the present invention may comprise the steps of providing baricitinib, such as baricitinib citrate of the present invention, and at least one excipient, and blending baricitinib and at least one excipient to obtain a composition.
  • the blend may be agglomerated into granules, and optionally compressed into tablets or filled into capsules.
  • the invention relates to the pharmaceutical composition as defined above for use as a medicament.
  • the invention relates to the pharmaceutical composition as defined above for use in the treatment of one or more condition(s) selected from the group consisting of atopic dermatitis, inflammatory disease, rheumatoid arthritis, systemic lupus erythematosus, diabetic nephropathy and psoriasis.
  • the present invention relates to the pharmaceutical composition as defined above for use in the treatment of rheumatoid arthritis.
  • the following non-limiting examples are illustrative of the disclosure and are not to be interpreted to be in any way limiting for the scope of the invention.
  • PXRD was performed with a PANalytical X'Pert PRO diffractometer equipped with a theta/theta coupled goniometer in transmission geometry, Cu-Kalphal ,2 radiation (wavelength 0.15419 nm) with a focusing mirror and a solid state PIXcel detector.
  • Diffractograms were recorded at a tube voltage of 45 kV and a tube current of 40 mA, applying a stepsize of 0.013° 2-Theta with 40s per step (255 channels) in the angular range of 2° to 40° 2-Theta at ambient conditions.
  • a typical precision of the 2-Theta values is in the range of ⁇ 0.2° 2-Theta, preferably in the range of ⁇ 0.1° 2-Theta.
  • the reflection of the crystalline form of baricitinib monocitrate that appears for example at 4.6° 2-Theta can appear between 4.4° and 4.8° 2-Theta, preferably between 4.5° and 4.7° 2-Theta on most X-ray diffractometers under standard conditions.
  • the reflection of the crystalline form of baricitinib dicitrate that appears for example at 5.1° 2-Theta can appear between 4.9° and 5.3° 2-Theta, preferably between 5.0° and 5.2° 2- Theta on most X-ray diffractometers under standard conditions.
  • Baricitinib free base (401 mg, 1.1 mmol, e.g. prepared according to the teaching of WO 2009/114512 Al, Examples 70 or 78) and citric acid (229 mg, 1.2 mmol) were suspended in acetonitrile (5 mL) and slurried at room temperature for 18 hours. The solid was collected by filtration and dried under vacuum at room temperature for 24 hours. Yield: 373 mg (61% of theory)
  • a representative powder X-ray diffractogram of the crystalline form of baricitinib monocitrate of the present invention obtained by the process according to Example 1 is displayed in Figure 1 and the corresponding reflection list is provided in Table 1 below.
  • Example 1.2 Amorphous baricitinib monocitrate (101 mg, prepared according to Example 2.1 herein) was slurried in acetonitrile (1 mL) at RT using a magnetic stirrer. After 3 days the solid was collected by filtration and dried under vacuum (35 mbar) at room temperature to yield the crystalline form of baricitinib monocitrate of the present invention.
  • Example 2 Preparation of amorphous baricitinib monocitrate
  • Baricitinib free base (223 mg, 0.6 mmol, e.g. prepared according to the teaching of WO 2009/114512 Al, Examples 70 or 78) and citric acid (118 mg, 0.6 mmol) were dissolved in aqueous acetonitrile (30 mL, 75% v/v) and subjected to the lyophilization conditions as set out below.
  • Baricitinib free base (214 mg, 0.6 mmol, e.g. prepared according to the teaching of WO 2009/114512 Al, Examples 70 or 78) and citric acid (114 mg, 0.6 mmol) were dissolved in 1,4- dioxane (30 mL) and subjected to the lyophilization conditions as set out below.
  • Baricitinib free base (215 mg, 0.6 mmol, e.g. prepared according to the teaching of WO 2009/114512 Al, Examples 70 or 78) and citric acid (114 mg, 0.6 mmol) were dissolved in a mixture of aqueous ethanol (50 mL, 80%> v/v) and 1,4-dioxane (10 mL) and subjected to the lyophilization conditions as set out below.
  • Lyophilization was performed with a Christ alpha 2-4 LSC plus lyophilizer. The following lyophilization program according to Table 3 was applied. temperature [°C] pressure [mbar] time [hh:mm] freezing -30 ambient 01 :30
  • Baricitinib free base (533 mg, 1.4 mmol, e.g. prepared according to the teaching of WO 2009/114512 Al, Examples 70 or 78) and citric acid (1109 mg, 5.8 mmol) were dissolved in acetonitrile (10 mL) upon heating to reflux. The clear solution was cooled to 0 °C in 2 hours whereupon a turbid solution was obtained. Subsequently, the solvent was removed in vacuo (rotary evaporator: 30 mbar, 40 °C bath temperature). The obtained residue was suspended in acetonitrile (5 mL) and treated in an ultrasonic bath for 15 min. The suspension was then slurried at room temperature for 18 hours. The solid was collected by filtration and dried under vacuum (35 mbar) at 40 °C for 24 hours. Yield: 722 mg (67% of theory)
  • a representative powder X-ray diffractogram of the crystalline form of baricitinib dicitrate of the present invention prepared according to Example 3.1 is displayed in Figure 3 and the corresponding reflection list is provided in Table 3 below.
  • Baricitinib free base (156 mg, 0.4 mmol, e.g. prepared according to the teaching of WO 2009/114512 Al, Examples 70 or 78) was dissolved in acetonitrile (5 mL) upon heating to reflux.
  • acetonitrile 5 mL
  • citric acid 670 microL, 1.4 mmol
  • ethanol 2.08 mol/L
  • the solvent of was removed in vacuo (rotary evaporator: 30 mbar, 40 °C bath temperature) and the obtained residue was suspended in acetonitrile (0.5 mL).
  • the suspension was treated in an ultrasonic bath for 5 min and subsequently stirred at room temperature for 18 hours.
  • the solid was collected by filtration and dried under vacuum (35 mbar) at room temperature for 24 hours.
  • Amorphous baricitinib dicitrate (159 mg, prepared according to Example 4.1 herein) was slurried in acetonitrile (1.5 mL) at RT using a magnetic stirrer. After 3 days the solid was collected by filtration and dried under vacuum (35 mbar) at room temperature to obtain the crystalline form of baricitinib dicitrate of the present invention.
  • Baricitinib free base (210 mg, 0.6 mmol, e.g. prepared according to the teaching of WO 2009/114512 Al, Examples 70 or 78) and citric acid (218 mg, 1.1 mmol) were dissolved in in a mixture of aqueous ethanol (60 mL, 20% v/v) and 1,4-dioxane (10 mL) and subjected to the lyophilization conditions as set out below. . _
  • Baricitinib free base (216 mg, 0.6 mmol, e.g. prepared according to the teaching of WO 2009/114512 Al , Examples 70 or 78) and citric acid (225 mg, 1.2 mmol) were dissolved in 1 ,4- dioxane (50 mL) and subjected to the lyophilization conditions as set out below.
  • Baricitinib free base (230 mg, 0.6 mmol, e.g. prepared according to the teaching of WO 2009/114512 Al, Examples 70 or 78) and citric acid (238 mg, 1.2 mmol) were dissolved in a aqueous acetonitrile (30 mL, 75% v/v) and subjected to the lyophilization conditions as set out below.
  • Lyophilization was performed with a Christ alpha 2-4 LSC plus lyophilizer. The following lyophilization program according to Table 4 was applied.
  • Eluent A 3.88g sulfamic acid, fill up with water to 1000 g
  • Eluent B 3.88 g sulfamic acid, fill up with water to 300 g and add 587 g acetonitrile
  • baricitinib As can be seen from Table 5 the phosphate and trifluoroacetate salts of baricitinib show only a slightly increased solubility in 0.1N aqueous hydrochloric acid. In contrast, the solubilities of baricitinib mono- and dicitrate of the present invention are more than 2-fold higher than the solubility of the free base.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des sels de citrate de baricitinib, en particulier de mono- et dicitrate de baricitinib, ainsi que leurs formes cristallines et amorphes, et leurs procédés de préparation. L'invention concerne en outre, une composition pharmaceutique comprenant une quantité efficace et/ou prédéterminée d'un ou plusieurs sels de citrate de baricitinib et l'utilisation de ladite composition pharmaceutique en tant que médicament, en particulier pour le traitement de la polyarthrite rhumatoïde.
PCT/EP2017/078044 2016-11-29 2017-11-02 Sels de citrate d'un inhibiteur de janus kinase (jak) Ceased WO2018099680A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16201249.6 2016-11-29
EP16201249.6A EP3327020A1 (fr) 2016-11-29 2016-11-29 Sels de citrate d'un inhibiteur de kinase de janus (jak)

Publications (1)

Publication Number Publication Date
WO2018099680A1 true WO2018099680A1 (fr) 2018-06-07

Family

ID=57442520

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2017/078044 Ceased WO2018099680A1 (fr) 2016-11-29 2017-11-02 Sels de citrate d'un inhibiteur de janus kinase (jak)

Country Status (2)

Country Link
EP (1) EP3327020A1 (fr)
WO (1) WO2018099680A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020163431A1 (fr) 2019-02-05 2020-08-13 Teva Pharmaceuticals International Gmbh Formes solides cristallines de baricitinib
WO2020181034A1 (fr) * 2019-03-05 2020-09-10 Incyte Corporation Inhibiteurs de la voie jak1 pour le traitement d'un dysfonctionnement chronique de l'allogreffe pulmonaire
CN116751204A (zh) * 2023-06-14 2023-09-15 枣庄学院 一种巴瑞克替尼-没食子酸共晶及其制备方法和应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009114512A1 (fr) 2008-03-11 2009-09-17 Incyte Corporation Dérivés d'azétidine et de cyclobutane en tant qu'inhibiteurs de janus kinase (jak)
WO2015145286A1 (fr) 2014-03-28 2015-10-01 Sun Pharmaceutical Industries Limited Forme amorphe de baricitinib
WO2015166434A1 (fr) 2014-05-01 2015-11-05 Sun Pharmaceutical Industries Limited Forme cristalline de baricitinib
CN105566332A (zh) 2016-01-29 2016-05-11 上海宣创生物科技有限公司 巴瑞克替尼三氟乙酸盐a晶型和b晶型及其制备方法
CN105601635A (zh) 2016-02-01 2016-05-25 上海宣创生物科技有限公司 巴瑞克替尼磷酸盐的a晶型、h晶型和i晶型及其制备方法
CN105693731A (zh) 2016-01-26 2016-06-22 上海宣创生物科技有限公司 巴瑞克替尼a晶型及其制备方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009114512A1 (fr) 2008-03-11 2009-09-17 Incyte Corporation Dérivés d'azétidine et de cyclobutane en tant qu'inhibiteurs de janus kinase (jak)
WO2015145286A1 (fr) 2014-03-28 2015-10-01 Sun Pharmaceutical Industries Limited Forme amorphe de baricitinib
WO2015166434A1 (fr) 2014-05-01 2015-11-05 Sun Pharmaceutical Industries Limited Forme cristalline de baricitinib
CN105693731A (zh) 2016-01-26 2016-06-22 上海宣创生物科技有限公司 巴瑞克替尼a晶型及其制备方法
CN105566332A (zh) 2016-01-29 2016-05-11 上海宣创生物科技有限公司 巴瑞克替尼三氟乙酸盐a晶型和b晶型及其制备方法
CN105601635A (zh) 2016-02-01 2016-05-25 上海宣创生物科技有限公司 巴瑞克替尼磷酸盐的a晶型、h晶型和i晶型及其制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SMITH, D.K.: "A FORTRAN Program for Calculating X-Ray Powder Diffraction Patterns", April 1963, LAWRENCE RADIATION LABORATORY
VITALIJ K. PECHARSKY; PETER Y. ZAVALIJ: "Fundamentals of Powder Diffraction and Structural Characterization of Materials", 2003, KLUWER ACADEMIC PUBLISHERS, pages: 3

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020163431A1 (fr) 2019-02-05 2020-08-13 Teva Pharmaceuticals International Gmbh Formes solides cristallines de baricitinib
WO2020181034A1 (fr) * 2019-03-05 2020-09-10 Incyte Corporation Inhibiteurs de la voie jak1 pour le traitement d'un dysfonctionnement chronique de l'allogreffe pulmonaire
CN114007621A (zh) * 2019-03-05 2022-02-01 因赛特公司 用于治疗慢性肺同种异体移植物功能障碍的jak1途径抑制剂
US11406640B2 (en) 2019-03-05 2022-08-09 Incyte Corporation JAK1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
US11896595B2 (en) 2019-03-05 2024-02-13 Incyte Corporation JAK1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
IL285999B1 (en) * 2019-03-05 2025-09-01 Incyte Corp JAK1 inhibitor pathway for the treatment of chronic lung allograft dysfunction
IL285999B2 (en) * 2019-03-05 2026-01-01 Incyte Corp JAK1 inhibitor pathway for the treatment of chronic lung allograft dysfunction
CN116751204A (zh) * 2023-06-14 2023-09-15 枣庄学院 一种巴瑞克替尼-没食子酸共晶及其制备方法和应用

Also Published As

Publication number Publication date
EP3327020A1 (fr) 2018-05-30

Similar Documents

Publication Publication Date Title
US20250188054A1 (en) Crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
US12410189B2 (en) Polymorphs and solid forms of (S)-2-2((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9- yl)amino)propanamide, and methods of production
JP6705833B2 (ja) イブルチニブとカルボン酸との共結晶
JP6211072B2 (ja) ダサチニブと、選択された共結晶形成剤とを含んでなる多成分結晶
EP2909191B1 (fr) Système cristallin multicomposant comprenant du nilotinib et des formateurs de co-cristal sélectionnés
WO2013189910A1 (fr) Cristaux multicomposants comprenant du mésilate d'imatinib et des agents de co-cristallisation choisis
KR102878525B1 (ko) 피리미디닐아미노-피라졸 화합물의 다형체와 고체 형태, 그리고 생산 방법
EP3728261B1 (fr) Co-cristal d'inhibiteur de janus kinase disponible par voie orale
US20180222903A1 (en) New crystalline form and acetic acid adducts of palbociclib
TW202108581A (zh) N-(5-(5-((1r,2s)-2氟環丙基)-1,2,4-㗁二唑-3-基)-2-甲基苯基)咪唑并[1,2-a]吡啶-3-甲醯胺之結晶型
WO2018099680A1 (fr) Sels de citrate d'un inhibiteur de janus kinase (jak)
CA3042738A1 (fr) Nouvelles formes cristallines du lesinurad
EP3459538B1 (fr) Sels cristallins d'un promédicament de dextroamphétamine
US9981912B2 (en) Cocrystal of lorcaserin, preparation methods, pharmaceutical compositions and uses thereof
US20250002453A1 (en) Pharmaceutically acceptable salt of eliglustat and crystal form thereof
WO2020187674A1 (fr) Hémisuccinate de (s)-[3,4-difluoro-2-(2-fluoro-4-iodophénylamino)phényl][3-hydroxy-3-(pipéridin-2-yl) azétidin-1-yl]méthanone cristallin
JP2025511099A (ja) Ｎ－（５－（（６，７－ジメトキシキノリン－４－イル）オキシ）ピリジン－２－イル）－１－プロピル－４－（２，２，２－トリフルオロエトキシ）－１ｈ－ピラゾール－３－カルボキサミド塩酸塩の新たな形態
EP3333154A1 (fr) Forme cristalline d'un antagoniste sélectif du récepteur 5-ht6
HK40020487A (en) Polymorphs and solid forms of gdc-0077, and methods of production thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17791424

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17791424

Country of ref document: EP

Kind code of ref document: A1